Inogen (INGN) Q1 2026 earnings review
International Growth Masks Deteriorating Domestic Performance
Inogen’s Q1 2026 results present a fractured narrative. On the surface, the company delivered a stable 3.4% YoY revenue growth ($85.1M), narrowly beating internal targets. But peeling back the layers reveals that growth is entirely dependent on International Sales (+17.8% YoY), while the core U.S. Sales (-4.8%) and U.S. Rentals (-8.0%) continue to contract. More troublingly, the highly-touted 'return to profitability' narrative from 2025 has completely reversed. Adjusted EBITDA slipped back into negative territory (-$1.4M) as the company ramped up R&D spending for new product rollouts. While management repurchased 298,100 shares under a new $30M program and guided for a 6% full-year revenue growth, the implied steep acceleration required in the back half of the year leaves a thin margin for error.
🐂 Bull Case
International sales are accelerating, up 17.8% YoY to $37.7M. The launch of the Rove 6 portable oxygen concentrator in Brazil signals further penetration into under-served global markets.
The U.S. launch of Aurora CPAP masks officially thrusts Inogen into the massive obstructive sleep apnea (OSA) market, opening a multi-billion dollar growth frontier outside of pure oxygen therapy.
🐻 Bear Case
U.S. Sales fell 4.8% and Rentals fell 8.0% YoY. If Inogen cannot stabilize its domestic footprint, international gains will be entirely absorbed by domestic bleeding.
After achieving positive Adjusted EBITDA in mid-2025, margins reversed back to negative in Q4 2025 and Q1 2026. The cost of commercializing new products is eating the bottom line.
⚖️ Verdict: ⚪
Neutral. The transition to a multi-product respiratory platform is showing tangible milestones (Aurora CPAP, Simeox trials), but the financial translation is messy. Domestic weakness and retreating margins make this a 'show-me' story for the promised H2 2026 acceleration.
Key Themes
International Sales Leading the Turnaround
International B2B and direct channels are single-handedly carrying the company's top line. International Sales grew an impressive 17.8% YoY to $37.7M. The recent launch of the Rove 6 portable oxygen concentrator in Brazil provides a specific catalyst for ongoing momentum in this geography.
Domestic Deterioration is Entrenched
The legacy U.S. business remains stubbornly weak. U.S. Sales declined 4.8% to $34.7M, showing no signs of escaping the negative trajectory established in 2025. Meanwhile, U.S. Rentals plummeted 8.0% to $12.7M. The continuous decline in these high-margin segments contradicts the idea of a fully stabilized domestic channel.
R&D Investments Erase Profitability Turnaround
Inogen spent much of 2025 touting its return to profitability. However, Adjusted EBITDA reversed from a positive $0.04M in 25Q1 to negative $1.4M in 26Q1. Management explicitly linked this margin compression to elevated R&D investments needed to sustain future growth (e.g., the IMPACTS-200 trial). This creates execution risk: investors are footing the bill for innovation today, relying on management's promise of profitability tomorrow.
Innovation Pipeline Hits the Commercial Market
The company's transformation from a pure-play oxygen concentrator maker to a diversified respiratory platform reached a critical milestone this quarter. Inogen formally introduced its Aurora CPAP masks in the U.S. market, marking its official entry into the obstructive sleep apnea space. Furthermore, patient enrollment commenced for the IMPACTS-200 U.S. reimbursement trial for the Simeox airway clearance device.
Other KPIs
Stable. Total GAAP gross margin expanded slightly by 30 basis points from 44.2% a year ago. Adjusted gross margin hit 44.7%, driven by underlying cost improvements in the total cost of revenue. This indicates supply chain efficiency is holding up despite mix shifts.
The balance sheet remains pristine with zero debt. Inogen initiated its previously announced $30M share repurchase program, buying back 298,100 shares for $1.9M. This signals management's belief that equity is undervalued relative to their long-term turnaround target.
Guidance
Stable. The midpoint of $95.5M implies a 3.5% YoY growth rate. This closely mirrors the 3.4% growth delivered in Q1, indicating that any aggressive acceleration from the new Aurora CPAP mask launch is not expected to move the needle immediately.
Accelerating implied in H2. The midpoint implies a 6.0% YoY growth rate relative to FY25. Given that H1 is pacing at ~3.5% growth, the company is baking in a steep acceleration for the second half of the year, likely counting heavily on International momentum and scaled rollout of new product lines.
Management reiterated its commitment to driving 'positive adjusted EBITDA improvement in 2026.' However, after printing a -$1.4M loss in Q1, they are digging out of a hole early in the year.
Key Questions
Bridge to Profitability
With Q1 Adjusted EBITDA dipping back into the red due to R&D investments, what is the specific quarterly timeline for returning to positive Adjusted EBITDA, and how will Simeox trial costs impact this trajectory through 2026?
Domestic Stabilization
U.S. Sales and Rentals continue to decline near high single-digits. At what point does management expect these legacy domestic channels to completely stabilize or return to growth?
Aurora CPAP Market Share
With the Aurora CPAP masks officially launched in the U.S., how much revenue contribution is embedded in the second-half acceleration implied by your 6% full-year revenue guidance?